Abstract

A nanometric pharmaceutical composition in the form of liposomes or a nanoemulsion containing interference RNA strands comprising one or more of the following specific siRNA sequences: SEQ ID NO: 1; SEQ ID NO: 2; or SEQ ID NO: 3.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 38/46 - Hydrolases (3)
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 9/107 - Emulsions
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 35/00 - Antineoplastic agents
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

The present invention relates to packaging for baled materials that includes at least one first packaging strip (1, 2, 4, 5, 10, 100) that is folded along parallel fold lines to form a first plurality of strip sections, the plurality of strip sections being dimensioned to wrap the bale in a first direction so that, once the bale has been wrapped, at least one end strip section can overlap another strip of the first plurality of strip sections; and an adhesive cellulose-microfibril solution applied to at least one adhesive application region between the overlapping strip sections. The first adhesive application region is a flat region separated from the parallel fold lines of the overlapping strip sections and separated from the free edges of the overlapping strip sections.

IPC Classes  ?

• B65B 27/12 - Baling or bundling compressible fibrous material, e.g. peat
• B65B 11/48 - Enclosing articles, or quantities of material, by folding a wrapper, e.g. a pocketed wrapper, and securing its opposed free margins to enclose contents
• B65B 13/02 - Applying and securing binding material around articles or groups of articles, e.g. using strings, wires, strips, bands or tapes
• B65B 51/02 - Applying adhesives or sealing liquids
• C09J 11/08 - Macromolecular additives

Abstract

The present invention relates to a nanometric-scale composition in the form of liposomes or nanoemulsions containing strands of interfering RNA (siRNA) capable of silencing the gene responsible for the expression of superexposed adhesion proteins in tumours, such as the enzyme ecto-5'-nucleotidase/CD73 (CD73) which is superexpressed in multiform glioblastoma and in other types of tumour. The binding of the liposomes or nanoemulsions to the siRNA promotes a site-directed release complex capable of being incorporated into various types of formulation, such as an intratumoral or intravenous injection or nasal administration.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention is the production of a multifunctional nanoparticulate black pigment created from the raw material rice husk. The method includes two procedures for producing said pigment using two ovens, the first being a pyrolysis oven created by the author of the present patent and the second oven being a tubular model with closed sides. Said pigment is characterized by being formed predominantly of silica, and is produced by a process of pyrolysis. The invention therefore makes it possible to produce a novel inorganic pigment from rice husk ashes of organic origin, thereby benefiting the industrial sector, which is in need of techniques that contribute towards compliance with socio-environmental demands.

IPC Classes  ?

• C09C 1/28 - Compounds of silicon
• C09C 1/40 - Compounds of aluminium
• C09B 61/00 - Dyes of natural origin prepared from natural sources
• C09D 7/12 - Other additives

Abstract

Metal-containing methacrylates incorporated into polymeric materials with antimicrobial capacity for biomedical applications, and more particularly for dental purposes, are provided. The incorporation of metal-containing methacrylates such as calcium methacrylate, tin methacrylate, copper methacrylate, silver methacrylate, in combination or alone, for potentializing antimicrobial effect of cements, in particular, to biomaterial compositions including metal containing methacrylates, such as calcium, tin, copper, silver, nickel, titanium and iron methacrylates, in the formulation of biomaterials for applications in human health provides advantages, particularly in dentistry, and allows for expressive antimicrobial activity to dental compositions, so as to be useful in dental prosthesis, operative dentistry, orthodontics, pediatric dentistry, implantodontics, and endodontics.

IPC Classes  ?

• A61K 6/889 - Polycarboxylate cementsGlass ionomer cements
• A61K 6/16 - Refractive index
• A61K 6/25 - Compositions for detecting or measuring, e.g. of irregularities on natural or artificial teeth
• A61K 6/62 - Photochemical radical initiators
• A61K 6/69 - Medicaments
• A61K 6/70 - Preparations for dentistry comprising inorganic additives
• A61K 6/76 - Fillers comprising silicon-containing compounds
• A61K 6/891 - Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

pruni xanthan, wherein the matrix is made of pure or combined xanthan varieties in any proportion, said matrix comprising between 1% and 95% by weight of the total weight of the composition, and additives or excipients; b) at least one anaesthetic, in a proportion of 0.1% to 50% by weight of the total weight of the composition. The topical anaesthetic bioadhesives (TABs) are also described, and they may be applied to the gingival mucosa and/or alveolar mucosa on the buccal (1) or lingual/buccal (2) surfaces with extensions and anatomical contours for crowns of the upper and lower dental arches.

IPC Classes  ?

• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 6/00 - Preparations for dentistry
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61L 24/08 - Polysaccharides
• A61K 9/06 - OintmentsBases therefor
• A61K 6/65 - Dyes
• A61K 6/69 - Medicaments
• A61K 6/78 - Pigments
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61L 24/00 - Surgical adhesives or cementsAdhesives for colostomy devices
• A61L 24/04 - Surgical adhesives or cementsAdhesives for colostomy devices containing macromolecular materials
• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient

Abstract

Filmogenic compositions are described for topical anaesthetic bioadhesives (TABs) comprising a) a xanthan biopolymer matrix selected from Xanthomonas species and pathovars, including Xanthomonas campestris pathovars campestris and maninhotis, and Xanthomonas arboricola pathovar pruni, a producer of pruni xanthan, wherein the matrix is made of pure or combined xanthan varieties in any proportion, said matrix comprising between 1% and 95% by weight of the total weight of the composition, and additives or excipients; b) at least one anaesthetic, in a proportion of 0.1% to 50% by weight of the total weight of the composition. The topical anaesthetic bioadhesives (TABs) are also described.

IPC Classes  ?

• A61K 9/70 - Web, sheet or filament bases
• A61F 13/02 - Adhesive bandages or dressings
• A61K 6/00 - Preparations for dentistry
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 31/085 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 23/02 - Local anaesthetics